Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women
Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part...
Saved in:
Published in | BMC women's health Vol. 23; no. 1; pp. 68 - 15 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
15.02.2023
BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored.
The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software.
Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002).
OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities. |
---|---|
AbstractList | Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored.BACKGROUNDPolycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored.The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software.METHODThe relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software.Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002).RESULTSix months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002).OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities.CONCLUSIONOCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities. Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored. The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software. Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002). OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities. Abstract Background Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and infertility. Metabolic abnormalities such as obesity, insulin resistance, glucose intolerance and cardiovascular problems constitute an essential part of PCOS, all of which can have significant long-term health consequences. Low-grade chronic inflammation demonstrated by persistent moderately elevated serum levels of inflammatory and coagulatory markers plays a critical role in the pathogenesis of PCOS. Oral contraceptive pills (OCPs) constitute the mainstay of pharmacologic therapy for women with PCOS to regularize cyclicity and ameliorate androgen excess. On the other hand, OCP use is associated with various venous thromboembolic and proinflammatory events in the general population. PCOS women always carriers the increased lifetime risk of these events. The studies on the effect of OCPs on inflammatory, coagulation and metabolic parameters in PCOS are less robust. Therefore in this study, we investigated and compared the messenger RNA (mRNA) expression profiles of genes implicated in inflammatory and coagulation pathways between drug-naive and OCP-treated PCOS women. The selected genes include intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1). Furthermore, the correlation between the selected markers and various metabolic indices in the OCP group has also been explored. Method The relative amounts of ICAM-1, TNF-α, MCP-1 and PAI-1 mRNA in peripheral blood mononuclear cells from 25 drug-naive PCOS subjects (controls) and 25 PCOS subjects who received OCPs containing 0.03 mg-ethinyl-estradiol and 0.15 mg-levonorgestrel for at least six months (cases) were estimated using real-time qPCR. The statistical interpretation was conducted using SPSS version 20.0 (SPSS, Inc, Chicago, IL), Epi Info version 2002 (Disease Control and Prevention Centres, Atlanta, GA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA) software. Result Six months of OCP therapy enhanced the expression of inflammatory genes viz ICAM-1, TNF-α and MCP-1 mRNA in PCOS women by 2.54, 2.05 and 1.74 folds, respectively, in this study. However, PAI-1 mRNA in the OCP group showed no significant increase. Furthermore, in cases, ICAM-1 mRNA expression positively correlated with body mass index (BMI) (p = 0.01), fasting insulin (p = 0.01), insulin 2 h p = 0.02), glucose 2 h (p = 0.01) and triglycerides (p = 0.01). TNF-α mRNA expression positively correlated with fasting insulin (p = 0.0007). MCP-1 mRNA expression positively correlated with (BMI) (p = 0.002). Conclusion OCPs helped reduce clinical hyperandrogenism and regularise menstrual cycles in women with PCOS. However, OCP use was associated with increased fold expression of inflammatory markers which positively correlated with metabolic abnormalities. |
ArticleNumber | 68 |
Author | Yousuf, Syed Douhath Dar, Mashooq Ahmad Urwat, Uneeb Andrabi, Syed Mudasir Ganie, Mohammad Ashraf Mudassar, Syed Rashid, Fouzia Zargar, Mohammad Afzal Manzoor-ul-Rehman, Mir |
Author_xml | – sequence: 1 givenname: Syed Douhath surname: Yousuf fullname: Yousuf, Syed Douhath – sequence: 2 givenname: Mohammad Ashraf surname: Ganie fullname: Ganie, Mohammad Ashraf – sequence: 3 givenname: Uneeb surname: Urwat fullname: Urwat, Uneeb – sequence: 4 givenname: Syed Mudasir surname: Andrabi fullname: Andrabi, Syed Mudasir – sequence: 5 givenname: Mohammad Afzal surname: Zargar fullname: Zargar, Mohammad Afzal – sequence: 6 givenname: Mashooq Ahmad surname: Dar fullname: Dar, Mashooq Ahmad – sequence: 7 givenname: Mir surname: Manzoor-ul-Rehman fullname: Manzoor-ul-Rehman, Mir – sequence: 8 givenname: Syed surname: Mudassar fullname: Mudassar, Syed – sequence: 9 givenname: Fouzia surname: Rashid fullname: Rashid, Fouzia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36793022$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1uEzEQxxdURD_gBTggH1OJBdv7fUGqIgqVWlKJcrYm3tnEldfe2t5AHosX4ZnwJi1qOXCwbHn-8_N45n-cHBhrMEneMPqesbr84BlvaJFSnsXF6iotnidHLK94WtZVfvDofJgce39LKavqonqZHGZl1WSU86NnzcKBJtKa4EDiENQGyaC0JrPF_PqUBIcQejSBgA7oPAlrJCs0SPDn4NB7ZQ2xHVEmRiVqPWpwBNo17iK91ShHjSkjs4v52VXKTt-RMPbWEYPSWa886UAG69Lfv8js5ut53KOkt8bKbUAi19hbCFNxAWIVg7MBlZl4V_PriCNgWjJo8L0yNhZGolBtIBJjTWu1VBM7qq_PLia1MmSweiu3PihJ7AbclvitaZ3tMYrmi2-n5Ec8m9iSfgCHLQmWtG5cpQam3kySveJV8qID7fH1_X6SfD__dDP_kl4uPse_XqYyL-uQStq1kheQdbwuOQcpl0ihQd5C01HaMQYs53WXsaWsyryEpiwRCsjbJZtmlJ0kF3tua-FWDE71sWhhQYndhXUrAS7-RqMAWlGaFxV0Bc2XTVfHiUuZ50UHGa_bNrI-7lnDuOyxlTiNXT-BPo0YtRYruxFNk0VCGQGze4CzdyP6IHrlp7mDQTt6wauqymmRFU2Uvn381t9HHrwXBfVeMBnBO-yEVAGC2nlRacGomGwu9jYXsRViZ3NRxFT-T-oD_T9JfwASBATJ |
CitedBy_id | crossref_primary_10_3390_healthcare12111108 crossref_primary_10_3923_ijbc_2024_01_10 crossref_primary_10_3389_fendo_2023_1273542 crossref_primary_10_3390_biomedicines13030709 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107753 crossref_primary_10_23736_S1593_232X_23_00578_7 crossref_primary_10_1007_s43032_024_01720_7 crossref_primary_10_3389_fendo_2024_1435698 crossref_primary_10_1080_14656566_2024_2371977 |
Cites_doi | 10.1097/MOH.0000000000000389 10.1016/j.fertnstert.2003.10.004 10.1097/01.GME.0000153888.94399.AF 10.1016/S0378-5122(02)00157-3 10.1016/j.fertnstert.2008.09.034 10.1016/j.dsx.2019.05.003 10.2169/internalmedicine.48.2177 10.1177/1076029617727857 10.2174/1389450120666190927122553 10.1080/09513590.2017.1395841 10.1093/humrep/17.7.1729 10.1038/s41598-019-46644-4 10.1084/jem.193.2.263 10.1016/j.cca.2019.09.010 10.1007/BF02786454 10.1159/000334175 10.1055/a-0992-9114 10.1530/EJE-08-0725 10.3389/fendo.2019.00879 10.1155/2018/9591509 10.1016/j.jpag.2016.06.010 10.1038/nprot.2008.73 10.1152/physrev.2001.81.4.1535 10.1016/j.ejogrb.2011.03.015 10.1371/journal.pone.0164021 10.2144/05391RV01 10.1056/NEJMcp033487 10.1038/nrendo.2009.62 10.1007/s12291-020-00901-w 10.1111/j.1538-7836.2005.01690.x 10.1016/j.cyto.2012.06.018 10.1093/qjmed/94.1.31 10.1016/j.metabol.2017.05.001 10.1016/j.fertnstert.2010.08.030 10.1530/JOE-13-0277 10.1210/jcem-21-11-1440 10.1242/jcs.00247 10.1016/j.mimet.2018.02.011 10.1093/humrep/15.4.785 10.1093/humrep/der096 10.1038/s41598-021-84586-y 10.3389/fendo.2019.00699 10.1161/CIRCRESAHA.117.306666 10.1507/endocrj.53.157 10.1016/j.thromres.2019.11.019 10.4103/jhrs.JHRS_95_18 10.1016/0092-8674(93)90367-Y 10.1016/S1043-2760(00)00272-1 10.2337/db08-0127 10.1038/srep17714 10.1016/j.ejogrb.2019.06.018 10.1016/j.dsx.2019.04.032 10.1186/s13048-019-0566-5 10.1080/13813455.2016.1190760 10.2174/1389450120666190715102510 10.1002/ijgo.13125 10.1210/jcem.85.7.6661 10.1093/humrep/dep459 10.1038/sj.ijo.0802502 10.1016/j.snb.2018.03.053 10.1007/BF00280883 10.1093/humrep/del407 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: The Author(s) 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s12905-023-02187-5 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 1472-6874 |
EndPage | 15 |
ExternalDocumentID | oai_doaj_org_article_a0700457af504b9f8001cc445fa328dd PMC9933286 36793022 10_1186_s12905_023_02187_5 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GrantInformation_xml | – fundername: DST ,New Delhi, Women scientist scheme grantid: SR/WOS-A/LS-642/2012(G). – fundername: ; grantid: SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G).; SR/WOS-A/LS-642/2012(G). |
GroupedDBID | --- 04C 0R~ 23N 2WC 53G 5VS 6J9 6PF 7R6 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACHQT ACIHN ACUHS ADBBV ADOJX ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BKEYQ BMC BMSDO BPHCQ BVXVI C6C CCPQU CITATION DIK DU5 E3Z EBD EBLON EBS ECF ECT EIHBH ESX EX3 F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO ICW IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PMKZF PQQKQ PROAC PSQYO PSYQQ QXPDG RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM 7X8 PPXIY 5PM PJZUB PUEGO |
ID | FETCH-LOGICAL-c468t-c0fdc25a3f28622accbe0a9e2da9f00f11a1428f31bc7646a966ea5a4db193023 |
IEDL.DBID | M48 |
ISSN | 1472-6874 |
IngestDate | Wed Aug 27 01:26:35 EDT 2025 Thu Aug 21 18:38:16 EDT 2025 Fri Jul 11 14:14:21 EDT 2025 Thu Jan 02 22:53:46 EST 2025 Tue Jul 01 00:26:25 EDT 2025 Thu Apr 24 22:59:02 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Monocyte chemoattractant protein-1 Polycystic ovary syndrome Coagulation Insulin resistance Inflammation Plasminogen activator inhabitor-1 Tumor necrosis factor-α Oral contraceptive pill |
Language | English |
License | 2023. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c468t-c0fdc25a3f28622accbe0a9e2da9f00f11a1428f31bc7646a966ea5a4db193023 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12905-023-02187-5 |
PMID | 36793022 |
PQID | 2777405359 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a0700457af504b9f8001cc445fa328dd pubmedcentral_primary_oai_pubmedcentral_nih_gov_9933286 proquest_miscellaneous_2777405359 pubmed_primary_36793022 crossref_citationtrail_10_1186_s12905_023_02187_5 crossref_primary_10_1186_s12905_023_02187_5 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-02-15 |
PublicationDateYYYYMMDD | 2023-02-15 |
PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC women's health |
PublicationTitleAlternate | BMC Womens Health |
PublicationYear | 2023 |
Publisher | BioMed Central BMC |
Publisher_xml | – name: BioMed Central – name: BMC |
References | S Nader (2187_CR44) 2007; 22 HJ Teede (2187_CR62) 2010; 93 J Panee (2187_CR67) 2012; 60 BK Tan (2187_CR58) 2008; 57 TD Schmittgen (2187_CR32) 2008; 3 MJ Chen (2187_CR54) 2010; 25 KM Seow (2187_CR56) 2012; 73 M Küçük (2187_CR61) 2011; 38 MA Ganie (2187_CR2) 2020; 149 F Cirillo (2187_CR4) 2019; 10 Q Fatima (2187_CR38) 2019; 13 N Koca (2187_CR68) 2021; 46 G Amato (2187_CR13) 2003; 101 2187_CR26 VL Armstrong (2187_CR45) 2001; 94 DS Milstone (2187_CR12) 2015; 117 B Xing (2187_CR28) 2018; 265 O Bilgir (2187_CR53) 2009; 48 DI Koleva (2187_CR7) 2016; 122 D Ferriman (2187_CR27) 1961; 21 W Hu (2187_CR36) 2011; 157 P Dulicek (2187_CR20) 2018; 24 M Kishimoto (2187_CR49) 2006; 53 R Deswal (2187_CR1) 2020; 13 M Luque-Ramírez (2187_CR55) 2009; 160 V Bianconi (2187_CR15) 2018; 25 LR Languino (2187_CR10) 1993; 73 K Gariani (2187_CR18) 2020; 185 M van Rooijen (2187_CR51) 2006; 4 SD Yousuf (2187_CR23) 2018; 148 T Urano (2187_CR16) 2019; 20 2187_CR33 S Nilsson (2187_CR47) 2001; 81 T Shah (2187_CR40) 2022 GS Hotamisligil (2187_CR64) 2003; 27 M Robinson-Rechavi (2187_CR48) 2003; 116 SF de Medeiros (2187_CR60) 2018; 2018 DB Petitti (2187_CR35) 2006; 4 BK Tan (2187_CR59) 2013; 219 SD Yousuf (2187_CR22) 2017; 30 MA Ganie (2187_CR39) 2019; 10 L Kong (2187_CR11) 2020; 21 Y Kawazoe (2187_CR66) 2001; 193 E Villa-Rodríguez (2187_CR34) 2018; 147 M Amiri (2187_CR21) 2017; 73 S Manzoor (2187_CR24) 2019; 9 A Lindholm (2187_CR57) 2011; 26 B Fève (2187_CR63) 2009; 5 H Tatsumi (2187_CR50) 2002; 42 DE Moller (2187_CR65) 2000; 11 E Hatziagelaki (2187_CR8) 2020; 128 K Elter (2187_CR43) 2002; 17 J-l Zhu (2187_CR42) 2019; 499 SUA Rasool (2187_CR3) 2019; 13 ASM Moin (2187_CR69) 2021; 11 P Jin (2187_CR19) 2018; 34 D Cibula (2187_CR46) 2000; 15 L Gao (2187_CR14) 2016; 11 NM Rashad (2187_CR6) 2019; 12 Q Sun (2187_CR5) 2019; 240 M Hemelaar (2187_CR52) 2005; 12 JS Hayflick (2187_CR9) 1998; 17 A Katz (2187_CR29) 2000; 85 ML Wong (2187_CR31) 2005; 39 WD James (2187_CR41) 2005; 352 DR Matthews (2187_CR30) 1985; 28 J Yarmolinsky (2187_CR17) 2016; 6 CS Atabekoglu (2187_CR37) 2011; 95 S Manzoor (2187_CR25) 2021; 36 |
References_xml | – volume: 101 start-page: 1177 issue: 6 year: 2003 ident: 2187_CR13 publication-title: Obstet Gynecol – volume: 25 start-page: 44 issue: 1 year: 2018 ident: 2187_CR15 publication-title: Curr Opin Hematol doi: 10.1097/MOH.0000000000000389 – ident: 2187_CR26 doi: 10.1016/j.fertnstert.2003.10.004 – volume: 12 start-page: 526 issue: 5 year: 2005 ident: 2187_CR52 publication-title: Menopause doi: 10.1097/01.GME.0000153888.94399.AF – volume: 42 start-page: 287 issue: 4 year: 2002 ident: 2187_CR50 publication-title: Maturitas doi: 10.1016/S0378-5122(02)00157-3 – volume: 93 start-page: 184 issue: 1 year: 2010 ident: 2187_CR62 publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2008.09.034 – volume: 13 start-page: 2098 issue: 3 year: 2019 ident: 2187_CR3 publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2019.05.003 – volume: 48 start-page: 1193 issue: 14 year: 2009 ident: 2187_CR53 publication-title: Intern Med doi: 10.2169/internalmedicine.48.2177 – volume: 24 start-page: 797 issue: 5 year: 2018 ident: 2187_CR20 publication-title: Clin Appl Thromb Hemost doi: 10.1177/1076029617727857 – volume: 21 start-page: 328 issue: 4 year: 2020 ident: 2187_CR11 publication-title: Curr Drug Targets doi: 10.2174/1389450120666190927122553 – volume: 34 start-page: 272 issue: 4 year: 2018 ident: 2187_CR19 publication-title: Gynecol Endocrinol doi: 10.1080/09513590.2017.1395841 – volume: 17 start-page: 1729 issue: 7 year: 2002 ident: 2187_CR43 publication-title: Hum Reprod doi: 10.1093/humrep/17.7.1729 – volume: 9 start-page: 10182 issue: 1 year: 2019 ident: 2187_CR24 publication-title: Sci Rep doi: 10.1038/s41598-019-46644-4 – volume: 193 start-page: 263 issue: 2 year: 2001 ident: 2187_CR66 publication-title: J Exp Med doi: 10.1084/jem.193.2.263 – volume: 499 start-page: 142 year: 2019 ident: 2187_CR42 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2019.09.010 – volume: 17 start-page: 313 issue: 3 year: 1998 ident: 2187_CR9 publication-title: Immunol Res doi: 10.1007/BF02786454 – volume: 73 start-page: 236 issue: 3 year: 2012 ident: 2187_CR56 publication-title: Gynecol Obstet Invest doi: 10.1159/000334175 – volume: 128 start-page: 723 issue: 11 year: 2020 ident: 2187_CR8 publication-title: Exp Clin Endocrinol Diabetes doi: 10.1055/a-0992-9114 – volume: 160 start-page: 469 issue: 3 year: 2009 ident: 2187_CR55 publication-title: Eur J Endocrinol doi: 10.1530/EJE-08-0725 – volume: 10 start-page: 879 year: 2019 ident: 2187_CR4 publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2019.00879 – volume: 2018 start-page: 9591509 year: 2018 ident: 2187_CR60 publication-title: Int J Inflamm doi: 10.1155/2018/9591509 – ident: 2187_CR33 – volume: 30 start-page: 58 issue: 1 year: 2017 ident: 2187_CR22 publication-title: J Pediatr Adolesc Gynecol doi: 10.1016/j.jpag.2016.06.010 – volume: 3 start-page: 1101 issue: 6 year: 2008 ident: 2187_CR32 publication-title: Nat Protoc doi: 10.1038/nprot.2008.73 – volume: 81 start-page: 1535 issue: 4 year: 2001 ident: 2187_CR47 publication-title: Physiol Rev doi: 10.1152/physrev.2001.81.4.1535 – volume: 157 start-page: 53 issue: 1 year: 2011 ident: 2187_CR36 publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2011.03.015 – volume: 11 issue: 10 year: 2016 ident: 2187_CR14 publication-title: PLoS ONE doi: 10.1371/journal.pone.0164021 – volume: 39 start-page: 75 year: 2005 ident: 2187_CR31 publication-title: Biotechniques doi: 10.2144/05391RV01 – volume: 352 start-page: 1463 issue: 14 year: 2005 ident: 2187_CR41 publication-title: Acne N Engl J Med doi: 10.1056/NEJMcp033487 – volume: 5 start-page: 305 issue: 6 year: 2009 ident: 2187_CR63 publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2009.62 – volume: 36 start-page: 278 issue: 3 year: 2021 ident: 2187_CR25 publication-title: Indian J Clin Biochem doi: 10.1007/s12291-020-00901-w – volume: 4 start-page: 77 issue: 1 year: 2006 ident: 2187_CR51 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2005.01690.x – volume: 60 start-page: 1 issue: 1 year: 2012 ident: 2187_CR67 publication-title: Cytokine doi: 10.1016/j.cyto.2012.06.018 – start-page: 205 volume-title: Managing the PCOS-related symptoms of hirsutism, acne, and female pattern hair loss. Polycystic ovary syndrome year: 2022 ident: 2187_CR40 – volume: 94 start-page: 31 issue: 1 year: 2001 ident: 2187_CR45 publication-title: QJM doi: 10.1093/qjmed/94.1.31 – volume: 73 start-page: 22 year: 2017 ident: 2187_CR21 publication-title: Metabolism doi: 10.1016/j.metabol.2017.05.001 – volume: 95 start-page: 295 issue: 1 year: 2011 ident: 2187_CR37 publication-title: Fertil Steril doi: 10.1016/j.fertnstert.2010.08.030 – volume: 219 start-page: 101 issue: 2 year: 2013 ident: 2187_CR59 publication-title: J Endocrinol doi: 10.1530/JOE-13-0277 – volume: 21 start-page: 1440 year: 1961 ident: 2187_CR27 publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem-21-11-1440 – volume: 116 start-page: 585 issue: Pt 4 year: 2003 ident: 2187_CR48 publication-title: J Cell Sci doi: 10.1242/jcs.00247 – volume: 147 start-page: 14 year: 2018 ident: 2187_CR34 publication-title: J Microbiol Methods doi: 10.1016/j.mimet.2018.02.011 – volume: 15 start-page: 785 issue: 4 year: 2000 ident: 2187_CR46 publication-title: Hum Reprod doi: 10.1093/humrep/15.4.785 – volume: 26 start-page: 1478 issue: 6 year: 2011 ident: 2187_CR57 publication-title: Hum Reprod doi: 10.1093/humrep/der096 – volume: 11 start-page: 1 issue: 1 year: 2021 ident: 2187_CR69 publication-title: Sci Rep doi: 10.1038/s41598-021-84586-y – volume: 10 start-page: 699 year: 2019 ident: 2187_CR39 publication-title: Front Endocrinol doi: 10.3389/fendo.2019.00699 – volume: 4 start-page: 813 issue: 11 year: 2006 ident: 2187_CR35 publication-title: Clin Adv Hematol Oncol – volume: 117 start-page: 166 issue: 2 year: 2015 ident: 2187_CR12 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.117.306666 – volume: 53 start-page: 157 issue: 2 year: 2006 ident: 2187_CR49 publication-title: Endocr J doi: 10.1507/endocrj.53.157 – volume: 185 start-page: 102 year: 2020 ident: 2187_CR18 publication-title: Thromb Res doi: 10.1016/j.thromres.2019.11.019 – volume: 13 start-page: 261 issue: 4 year: 2020 ident: 2187_CR1 publication-title: J Hum Reprod Sci doi: 10.4103/jhrs.JHRS_95_18 – volume: 73 start-page: 1423 issue: 7 year: 1993 ident: 2187_CR10 publication-title: Cell doi: 10.1016/0092-8674(93)90367-Y – volume: 11 start-page: 212 issue: 6 year: 2000 ident: 2187_CR65 publication-title: Trends Endocrinol Metab doi: 10.1016/S1043-2760(00)00272-1 – volume: 57 start-page: 1501 issue: 6 year: 2008 ident: 2187_CR58 publication-title: Diabetes doi: 10.2337/db08-0127 – volume: 6 start-page: 17714 year: 2016 ident: 2187_CR17 publication-title: Sci Rep doi: 10.1038/srep17714 – volume: 240 start-page: 36 year: 2019 ident: 2187_CR5 publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2019.06.018 – volume: 13 start-page: 1957 issue: 3 year: 2019 ident: 2187_CR38 publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2019.04.032 – volume: 12 start-page: 97 issue: 1 year: 2019 ident: 2187_CR6 publication-title: J Ovarian Res doi: 10.1186/s13048-019-0566-5 – volume: 46 start-page: 116 issue: 1 year: 2021 ident: 2187_CR68 publication-title: Miner Endocrinol – volume: 122 start-page: 223 issue: 4 year: 2016 ident: 2187_CR7 publication-title: Arch Physiol Biochem doi: 10.1080/13813455.2016.1190760 – volume: 148 start-page: S151 issue: Suppl year: 2018 ident: 2187_CR23 publication-title: Indian J Med Res – volume: 20 start-page: 1695 issue: 16 year: 2019 ident: 2187_CR16 publication-title: Curr Drug Targets doi: 10.2174/1389450120666190715102510 – volume: 149 start-page: 231 issue: 2 year: 2020 ident: 2187_CR2 publication-title: Int J Gynaecol Obstet doi: 10.1002/ijgo.13125 – volume: 85 start-page: 2402 issue: 7 year: 2000 ident: 2187_CR29 publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.85.7.6661 – volume: 25 start-page: 779 issue: 3 year: 2010 ident: 2187_CR54 publication-title: Hum Reprod doi: 10.1093/humrep/dep459 – volume: 27 start-page: S53 issue: Suppl 3 year: 2003 ident: 2187_CR64 publication-title: Int J Obes Relat Metab Disord doi: 10.1038/sj.ijo.0802502 – volume: 265 start-page: 403 year: 2018 ident: 2187_CR28 publication-title: Sens Actuators B Chem doi: 10.1016/j.snb.2018.03.053 – volume: 38 start-page: 54 issue: 1 year: 2011 ident: 2187_CR61 publication-title: Clin Exp Obstet Gynecol – volume: 28 start-page: 412 issue: 7 year: 1985 ident: 2187_CR30 publication-title: Diabetologia doi: 10.1007/BF00280883 – volume: 22 start-page: 317 issue: 2 year: 2007 ident: 2187_CR44 publication-title: Hum Reprod doi: 10.1093/humrep/del407 |
SSID | ssj0017857 |
Score | 2.3440866 |
Snippet | Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss, acne and... Abstract Background Polycystic ovary syndrome (PCOS) presents clinical symptoms of menstrual abnormalities, excessive hair growth (hirsutism), scalp hair loss,... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 68 |
SubjectTerms | Body Mass Index Chemokine CCL2 - genetics Contraceptives, Oral - therapeutic use Female Gene Expression Humans Inflammation Insulin Intercellular Adhesion Molecule-1 - genetics Intercellular Adhesion Molecule-1 - therapeutic use Leukocytes, Mononuclear - metabolism Monocyte chemoattractant protein-1 Oral contraceptive pill Plasminogen activator inhabitor-1 Plasminogen Activator Inhibitor 1 - genetics Plasminogen Activator Inhibitor 1 - therapeutic use Polycystic ovary syndrome Polycystic Ovary Syndrome - drug therapy Polycystic Ovary Syndrome - genetics RNA, Messenger - metabolism RNA, Messenger - therapeutic use Tumor Necrosis Factor-alpha Tumor necrosis factor-α |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NitswEFbLngql9L_pH1PoIUtrNrJlyz6moWG3kE2gu7A3I0tyY0jskDiheay-SJ-pM7IdNqW0l54C8Xg8Ft9YI2nmG8beS8UDI0zgSWGlJ4zIvSzWvkdkcLGOI-27-orJZXR-Lb7chDe3Wn1RTlhDD9wM3JkaEAF7KFUeDkSW5BjgcK2FCHMV-LEx9PXFOa9bTLXnBzIOZVciE0dnG9ptoUpkOrPk6Fbh0TTk2Pr_FGL-nil5a-oZP2QP2pgRho2tj9hdWz5m95sNN2jqiJ7cSaZ4J7jMc-VSVXYWVsViAf3paHYKh4RycOfjG8DADxA8Fuz3Nhe2hCoHoo9wu_mUngrKzK27smy66FqPQ_9iNJx4_PQj1NtltYbS0isWG2ha93g_f0D_6nKMvyiCIK_0vraA2FhWqibjqG8xOH6IoiR9k9EM1YEqDawwll8WZYWGAVVc7GhLAG2aF1lBulF6Nrwg6aKEVbXY6z3xTEO1U-s9dOwLKDSafj0Fxy4BXZY91BWY9fabVyoaGxJpJJ6y6_Hnq9G51_aF8LSI4trTg9xoP1RB7uN6zFdaZ3agEusbleSDQc65Ih65POCZlpGIFC7prAqVMBmGqwiCZ-ykrEr7goHlkZSBzDVqw9BGJHkYRomJE8OlibjqMd7BJNUtaTr17likbvEUR2kDrRS1pg5aadhjHw73rBrKkL9KfyL0HSSJ7tv9gU6Qtk6Q_ssJeuxdh90UPw-EElXaartJfYnxPXH4JD32vMHy4VFBJGk4_B6TRyg_suX4SlnMHQU5RrX44Ojl_zD-FbvnN57p8fA1O6nXW_sGI706e-uc-hc_xlM- priority: 102 providerName: Directory of Open Access Journals |
Title | Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36793022 https://www.proquest.com/docview/2777405359 https://pubmed.ncbi.nlm.nih.gov/PMC9933286 https://doaj.org/article/a0700457af504b9f8001cc445fa328dd |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ta9swENb6AqMwxt6XvYQb7EPL5s3ym-wPY7ShpR2kDV0LZV-MLMmtIbGzxCnNz9of2W_anRxny-j2JYb4dJbt56w76fQcY2-F5L4OtO-IwAgn0EHuZLHyHCKDi1UcKc_ur-gfR4fnwZeL8GKNteWOFg9wemtoR_WkzifDDzff55_R4D9Zg4-jj1OaS6F9xrQiydFownW2iSOToIoG_eD3qoKIQ9FunLm13Ra760eIWNfzVsYpS-d_mw_6dyrlH2PTwQN2f-FUwm6DgodszZSP2L1mRg6ajUaP7yQn2BJsarq0uSzXBsbFcAjbJ73BDiwzzsEuoE8BPUNAdBkwN4tk2RKqHIhfwk73U_4qSH1l7JlRU2bXOBy2j3q7fYfvvId6NqomUBq6xWIKTW0f5-cP2D47PsAjiqAVVGpeG0DwjCpZU-eosDFYAomiJH393gDVgSw1jNHZHxVlhR0D2pJxTXMG2KerIitIN0oPdo9IuihhXA3nak5E1FBdy8kcWnoGFOqdfN0BSz8BbRo-1BXoyezSKSU9GxJpJJ6w84P9s96hsygc4aggimtHublWXij93MOAzZNKZcaVifG0THLXzTmXRDSX-zxTIgoiiTGfkaEMdMbp5ftP2UZZleY5A8MjIXyRK9SGvk-Q5GEYJTpONBc64rLDeAuTVC1Y1am4xzC10VUcpQ3KUtSaWpSlYYe9W7YZN5wi_5XeI_QtJYkP3P5RTS7TxecllS6VKQiFzEM3yJIcwwCuVBCEufS9WOsOe9NiN8XvB6FElqaaTVNPYABAJD9Jhz1rsLy8VGsLHSZWUL7Sl9UzZXFlOcrR7cULRy_-qfMl2_Iay3N4-Ipt1JOZeY3-XZ112bq4EF22ubd_PDjt2lmSrjVk_D3d-_YLyQZSqw |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+contraceptive+pill+%28OCP%29+treatment+alters+the+gene+expression+of+intercellular+adhesion+molecule-1+%28ICAM-1%29%2C+tumor+necrosis+factor-%CE%B1+%28TNF-%CE%B1%29%2C+monocyte+chemoattractant+protein-1+%28MCP-1%29+and+plasminogen+activator+inhibitor-1+%28PAI-1%29+in+polycystic+ovary+syndrome+%28PCOS%29+women+compared+to+drug-naive+PCOS+women&rft.jtitle=BMC+women%27s+health&rft.au=Yousuf%2C+Syed+Douhath&rft.au=Ganie%2C+Mohammad+Ashraf&rft.au=Urwat%2C+Uneeb&rft.au=Andrabi%2C+Syed+Mudasir&rft.date=2023-02-15&rft.eissn=1472-6874&rft.volume=23&rft.issue=1&rft.spage=68&rft_id=info:doi/10.1186%2Fs12905-023-02187-5&rft_id=info%3Apmid%2F36793022&rft.externalDocID=36793022 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6874&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6874&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6874&client=summon |